ANI Pharmaceuticals (ANIP)

[silvr_surfr]

Yescarta is about to begin a phase 2 trial for Relapsed/Refractory Acute Lymphoblastic Leukemia. There are 15,000 new cases of this horrible disease each year. Below is a presentation of the phase 1 results which are dramatic (94% of patients achieved a response with undetectable MRD).

Zuma-3 Phase 1 Results

At $375K per treatment, 5,000 patients translates to $1.9B in revenue. At a 1% royalty rate, this translates to $19M a year to ANIP. Hopefully, once the initial start up investment is made in all of the car-t factories across the country, the price tag will come down and more patients will be able to access it.